Pipeline Pharmacological Therapies in Clinical Trial for COVID-19 Pandemic: a Recent Update
- PDF / 712,910 Bytes
- 13 Pages / 595.276 x 790.866 pts Page_size
- 93 Downloads / 183 Views
COVID-19 (ATY LAU AND A KONG, SECTION EDITORS)
Pipeline Pharmacological Therapies in Clinical Trial for COVID-19 Pandemic: a Recent Update Puja Kumari 1 & Kajal Rawat 1 & Lekha Saha 1
# Springer Nature Switzerland AG 2020
Abstract The emergence of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), responsible for causing coronavirus disease 2019 (COVID-19), marked the third time in the twenty-first century when a new, highly pathogenic human coronavirus outbreak has led to an epidemic. The COVID-19 epidemic has emerged in late December 2019 in Wuhan city of China and spread rapidly to other parts of the world. This quick spread of SARS-CoV-2 infection to many states across the globe affecting many people has led WHO to declare it a pandemic on March 12, 2020. As of July 4, 2020, more than 523,011 people lost their lives worldwide because of this deadly SARS-CoV-2. The current situation becomes more frightening as no FDA-approved drugs or vaccines are available to treat or prevent SARS-CoV-2 infection. The current therapeutic options for COVID-19 are limited only to supportive measures and non-specific interventions. So, the need of the hour is to search for SARS-CoV-2-specific antiviral treatments and to develop vaccines for SARS-CoV2. Also, it is equally important to maintain our immunity, and natural products and Ayurvedic medicines are indispensable in this regard. In this review, we discuss recent updates regarding various therapeutic approaches to combat COVID-19 pandemic and enlist the major pipeline drugs and traditional medicines that are under trial for COVID-19. Also, possible mechanisms involved in viral pathogenesis are discussed, which further allow us to understand various drug targets and helps in discovering novel therapeutic approaches for COVID-19. Altogether, the information provided in this review will work as an intellectual groundwork and provides an insight into the ongoing development of various therapeutic agents. Keywords COVID-19 . SARS-CoV-2 . Pipeline drugs . Pharmacological therapy . A recent update
Abbreviations COVID-19 SARS-CoV-2 SARS-CoV MERS-CoV WHO ARDS
Coronavirus disease 2019 Severe acute respiratory syndrome coronavirus 2 Severe acute respiratory syndrome coronavirus Middle East respiratory syndrome coronavirus World health organization Acute respiratory distress syndrome
This article is part of the Topical Collection on Covid-19 * Lekha Saha [email protected]; [email protected] 1
Department of Pharmacology, Post Graduate Institute of Medical Education & Research (PGIMER), 4th Floor, Research Block B, Chandigarh 160012, India
ACE2 TMPRSS2 RdRp 3CLPro PD1 IL-6 NK cell ARB NSAID rbACE2 BCG RCT EUA CQ HCQ MSC TCM
Angiotensin-converting enzyme 2 Transmembrane protease serine type 2 RNA-dependent RNA polymerase 3-chymotrypsin-like protease Programmed cell death protein Interleukin-6 Natural killer cell Angiotensin receptor blocker Nonsteroidal anti-inflammatory drug Recombinant bacterial ACE2 receptors Bacillus Calmette Guérin Randomized contro
Data Loading...
